Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDe Stefano, Nicola
dc.contributor.authorBarkhof, Frederik
dc.contributor.authorMontalban Gairín, Xavier
dc.contributor.authorAchiron, Anat
dc.contributor.authorDerfuss, Tobias
dc.contributor.authorChan, Andrew
dc.date.accessioned2022-09-12T08:25:22Z
dc.date.available2022-09-12T08:25:22Z
dc.date.issued2022-07
dc.identifier.citationde Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, et al. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 Jul;9(4):e1187.
dc.identifier.issn2332-7812
dc.identifier.urihttp://hdl.handle.net/11351/8138
dc.descriptionActive Relapsing Multiple Sclerosis; MRI; Cladribine
dc.description.abstractBackground and Objectives The onset of action for high-efficacy immunotherapies in multiple sclerosis (MS) is an important parameter. This study (MAGNIFY-MS) evaluates the onset of action of cladribine tablets by observing changes in combined unique active (CUA) MRI lesion counts during the first 6 months of treatment in patients with highly active relapsing MS. Methods MRI was performed at screening, baseline, and at months 1, 2, 3, and 6 after initiating treatment with cladribine tablets 3.5 mg/kg. CUA lesion counts, defined as the sum of T1 gadolinium-enhancing (Gd+) lesions and new or enlarging active T2 lesions (without T1 Gd+), were compared between postbaseline and the baseline period and standardized to the period length and the number of MRIs performed. Results Included in this analysis were 270 patients who received ≥1 dose of cladribine tablets. After treatment initiation, significant reductions in mean CUA lesion counts were observed from month 1 onward compared with the baseline period (−1.193 between month 1 and month 6, −1.500 between month 2 and month 6, and −1.692 between month 3 and month 6; all p < 0.0001). Mean T1 Gd+ lesion counts were decreased from month 2 onward compared with baseline (−0.857 at month 2, −1.355 at month 3, and −1.449 at month 6; all p < 0.0001), whereas the proportion of patients without any CUA lesions increased from 52.0% between month 1 and month 6 to 80.5% between month 3 and month 6. Discussion Findings suggest an early onset of action for cladribine tablets, with an increasing reduction in active MRI lesions over time. Trial Registration Information NCT03364036; Date registered: December 06, 2017.
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofseriesNeurology - Neuroimmunology & Neuroinflammation;9(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Imatgeria per ressonància magnètica
dc.subjectImmunoteràpia
dc.subjectComprimits (Medicina) - Ús terapèutic
dc.subject.meshMultiple Sclerosis
dc.subject.mesh/diagnostic imaging
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshImmunotherapy
dc.titleEarly Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1212/NXI.0000000000001187
dc.subject.decsesclerosis múltiple
dc.subject.decs/diagnóstico por imagen
dc.subject.decsimagen por resonancia magnética
dc.subject.decsinmunoterapia
dc.relation.publishversionhttps://doi.org/10.1212/NXI.0000000000001187
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[de Stefano N] Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. [Barkhof F] Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands. UCL Institute of Neurology, London, UK. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Achiron A] Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel. [Derfuss T] Department of Neurology, University Hospital Basel, Basel, Switzerland. [Chan A] Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
dc.identifier.pmid35701185
dc.identifier.wos000816701200018
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record